A promising means of rapid screening of extended-spectrum-b-lactamase (ESBL), AmpC b-lactamase, and co-production of ESBL and AmpC that combines resazurin chromogenic agar (RCA) with a combined disc method is here reported. Cefpodoxime (CPD) discs with and without clavulanic acid (CA), cloxacillin (CX) and CAþCX were evaluated against 86 molecularly confirmed b-lactamase-producing Enterobacteriaceae, including 15 ESBLs, 32 AmpCs, nine co-producers of ESBL and AmpC and 30 carbapenemase producers. The CA and CX synergy test successfully detected all ESBL producers (100% sensitivity and 98.6% specificity) and all AmpC producers (100% sensitivity and 96.36% specificity). This assay also performed well in screening for co-existence of ESBL and AmpC (88.89% sensitivity and 100% specificity). The RCA assay is simple and inexpensive and provides results within 7 hr. It can be performed in any microbiological laboratory, in particular, in geographic regions in which ESBL, AmpC or co-b-lactamase-producing Enterobacteriaceae are endemic.
false-negative ESBL results because strong expression of AmpC b-lactamases can mask the presence of ESBLs. Use of CA and CX together allows detection of coproduction of ESBL and AmpC (9) . In addition, AmpC producers and co-producers of AmpC and ESBL have also been reported to be resistant to third-generation cephalosporins, cephamycins or b-lactam/b-lactamase inhibitor combinations (10) . Infections caused by AmpC-producing organisms are typically associated with resistance to multiple antibiotics, including penicillins, oxyimino-7-a-methoxycephalosporins and monobactams (11, 12) . In general, AmpC type enzymes are poorly inhibited by b-lactamase inhibitors, especially CA. Phenotypic AmpC confirmation tests are generally based on inhibition of AmpC by either CX or boronic acid derivatives. Boronic acid also inhibits class A carbapenemases (13) , justifying the inclusion of CX in the present study. Moreover, co-expression of ESBL and AmpC b-lactamases results in less susceptibility to aztreonam and b-lactam/ b-lactamase inhibitors than occurs with either ESBL or AmpC b-lactamase alone (14) . This makes the selection of an effective antibiotic for the treatment of infections caused by these recalcitrant bacteria difficult.
A simple, rapid and inexpensive method for screening and discrimination between these enzymes at a phenotypic level could help clinicians to prescribe an appropriate chemotherapy. A combined disc method has been used extensively because it is relatively easy to prepare and perform. However, this test requires at least 18 hr or overnight to provide results. A resazurin reduction assay, a colorimetric method, is based upon the ability of active cells to reduce blue resazurin to pink resorufin (15) . A colorimetric (resazurin-containing) disc susceptibility method is reportedly highly reproducible (16) and has high sensitivity and specificity for detection and differentiation of carbapenemaseproducing Enterobacteriaceae (17) . CPD is an attractive indicator cephalosporin for detection of ESBL production and may be used for screening according to European Committee on Antimicrobial Susceptibility Testing guidelines. Several methods have been proposed for phenotypic confirmation of ESBL and AmpC b-lactamases, including the Etest combined disc method (e.g., MAST D68C test), double disc synergy test and automated broth microdilution test. These methods usually take at least 18 hr to provide results (9, 18, 19) . Hence, the present study investigated a RCA method together with CPD discs alone or supplemented with CA, CX, and both CA and CX to screen for and discriminate between ESBL, AmpC, and co-existence of ESBL and AmpC among Enterobacteriaceae.
MATERIALS AND METHODS

Bacterial isolates
In the present study, the performance of the RCA assay in rapid screening and discrimination of ESBL, AmpC, and co-producers of ESBL and AmpC was evaluated in 86 b-lactamase-producing Enterobacteriaceae isolates. The organisms used in the present study are summarized in Table 1 (17, 20) . The molecular types included 15 Ambler class A ESBL producers (three CTX-M-3, one CTX-M-15, one SHV-27, one SHV-18, one SHV, one TEM-214, one TEM-10, one TEM-70, one CTX-M-15þSHV-27, one SHV-27þTEM-53, one SHV-27þTEM-71, one SHV-110þTEM-84 and one CTX-MþSHVþTEM), 32 Ambler class C AmpC producers (six DHA family, seven CIT family, two MOX family, 11 EBC family and six FOX family) and nine coproducers of ESBL and AmpC (one TEMþACT-type, four CTX-MþACT-types, one TEMþSHVþACT-type, one TEMþCTX-MþACT-type, one SHVþACT type and one SHVþCTX-M-ACT-type). Thirty carbapenemase-producing isolates (eight KPC, 11 MBL and 11 OXA-48 producers) were also included to validate the performance of the RCA plate assay. A reference strain Escherichia coli ATCC 25922 was used as a negative b-lactamase control strain. The following b-lactamase-producing isolates obtained from the ATCC and NCTC were used as controls; Enterobacter cloacae ATCC BAA-1143 (bla ACT-32 ), E. coli NCTC 13352 (bla TEM-10 ) and E. coli NCTC 13353 (bla CTX-M-15 ).
RCA plate and disc preparations
Resazurin chromogenic agar plates were prepared according to methods described in previous studies (16, 17) . Briefly, 10 mL of sterile 2.5 mg/mL resazurin sodium salt (Sigma-Aldrich, Poole, UK) was added to 990 mL of sterile Mueller-Hinton agar 45-50°C (Oxoid, Cambridge, UK), then mixed gently and poured into Petri dishes to achieve an approximately 4 mm depth.
For the preparation of the antibiotic-or b-lactamase inhibitor-containing discs, 10 mg of CPD discs (Mast Group, Merseyside, UK) were supplemented with 10 mL of 1 mg/mL CA (Sigma-Aldrich), 10 mL of CX (Sigma-Aldrich) at a concentration of 50 mg/mL, or impregnated with both CA and CX. MER discs (10 mg) were prepared by adding 10 mL of MER (Sigma-Aldrich) at a concentration of 1 mg/mL to blank discs (6.5 mm diameter; MAST Group). Prior to performing disc diffusion susceptibility testing, the discs were air-dried in a biosafety cabinet for 1 hr.
Disc diffusion susceptibility testing
The algorithm for phenotypic screening of ESBL, AmpC and co-producers of ESBL and AmpC is illustrated in Figure 1 . The experimental procedure for disc diffusion susceptibility testing was carried out according to the CLSI guidelines (21) . Briefly, a sterile swab soaked in a 0.5 McFarland standard of test organism was spread on the entire surface of a RCA plate. Discs containing CPD alone, CPD plus CA, CPD plus CX, CPD plus CA and CX and MER alone were placed equidistantly on the RCA's surface. MER discs were used to screen for carbapenem resistance, including carbapenemase production. Following incubation at 37°C for 7 hr, inhibition zone diameters were scrupulously measured and interpreted by observing a change in the medium from the original blue (resazurin) to pink (resorufin). The interpretation criteria for screening and differentiation of ESBL, AmpC and co-b-lactamases were based upon a previous report, as presented in Table 2 (19) . An increase in zone diameter (!5 mm) of CPD supplemented with b-lactamase inhibitor compared with CPD alone was considered to denote synergistic activity. In interpretation of the results, CA synergy was considered a positive result for ESBL, whereas CX synergy and CA plus CX synergy were noted as positive results for AmpC and co-production of ESBL and AmpC, respectively. A zone diameter of MER < 25 mm was used at a cut-off point to screen for the presence of carbapenemases. Sensitivity and specificity of the RCA assay with a combined disc method were calculated by comparing the results with molecular types from PCR and sequencing data. A box-and-whisker plot was analyzed using SPSS statistical analysis program Version 18 to elucidate the 
RESULTS
The use of the RCA assay together with a combined disc method for phenotypic confirmation of ESBL, AmpC and co-expression of ESBL plus AmpC provided clear inhibition zone diameters within 7 hr (Fig. 2) . Figure 3 shows the distribution of the zone diameters of CPD producers with a median zone diameter 25 mm (range, 23-27 mm) (Fig. 3a) . Substantially greater zone diameters on CA-containing discs than on discs without CA was observed only for ESBL-producing isolates. The mean difference in zone size between CPD plus CA and CPD alone was 14.6 mm (range, 5-17.5 mm). AmpC producers (mean ¼ 0.48 mm; range, 1.5-3.5 mm), co-producers of ESBL and AmpC (mean, 2.72 mm; range, 1.5-8.5 mm) and carbapenemase-producing isolates (mean, 0.37 mm; range, 0-5.5 mm) did not demonstrate markedly greater zone diameters. The RCA assay with combined disc method detected all test ESBL producers with 100% sensitivity and 98.6 % specificity (Table 2) . A false-positive result was observed in an OXA-48-producing E. coli.
In AmpC producers, greater median zone diameters were seen in CX-containing discs. CPD plus CX and CPD plus CX plus CA both had median zone diameters of 20 mm and a range of 12-26 mm. The median zone diameter of CPD against these isolates was 7.25 mm (range, 6.5-20 mm), which is similar to that for CPD plus CA (median, 8 mm; range, 6.25-21 mm). MER discs inhibited the growth of AmpC-producing isolates with a median zone diameter of 25 mm and range 23-28 mm (Fig. 3b) . The mean difference in zone diameters between CPD plus CX and CPD alone was 10.1 mm (range, 5.5-16.5 mm) against AmpC producers, whereas no dramatic differences in mean zone diameters were observed in ESBL producers (mean, 0.33 mm; range, 0-2 mm), co-producers of ESBL and AmpC (mean, 4.33 mm; range, 1 7.5 mm) or carbapenemase producers (mean, 0.88 mm; range, 0-9.5 mm). The RCA assay performed extremely well in screening for AmpCproducing strains by detecting all test AmpC producers (100% sensitivity); however, there were two falsepositives in KPC-3-producing K. pnuemoniae and OXA-48-producing E. coli (96.36% specificity; Table 2 ). For screening of ESBL and AmpC-co-producing Enterobacteriaceae, CPD discs alone exhibited a median zone diameter of 9 mm (range, 6.5-22 mm). CPD plus CA (median, 15 mm; range, 6.5-22 mm) and CPD plus CX (median, 14 mm; range, 10 27 mm) showed slightly greater median zone diameters than CPD alone. CPD plus CA plus CX demonstrated excellent activity in inhibiting the growth of ESBL and AmpC co-producers, median zones being significantly greater (median, 24 mm; range, 21-27 mm) than for CPD alone, CPD plus CA and CPD plus CX. The median zone diameter and zone range of MER against these isolates were 25 mm and 23-26 mm, respectively (Fig. 3c) . The mean differences in zone diameter between CPD plus CA and CX and CPD plus CA, and between CPD plus CA and CX and CPD plus CX, were also calculated. The mean difference in zone diameter between CPD plus CA and CX and CPD plus CA was 11. 61 mm (range, 5-19.5 mm). A similar result was observed for CPD plus CA and CX versus CPD plus CX. The sensitivity and specificity of the RCA assay with the combined disc method were 88.89% and 100%, respectively ( Table 2) . The assay failed to detect ESBL activity in a SHV plus ACT-producing E. aerogenes. Furthermore, in carbapenemase-producing isolates, the median zone diameters of CPD with and without CA, CX, or CA and CX did not differ markedly, whereas the ranges did vary. The MER disc alone had a median zone diameter of 17 mm and range 6.5-25 mm. A reference strain E. coli ATCC 25922 was inhibited by a CPD disc alone with zone diameter 25 mm, which is in the susceptible range according to the CLSI breakpoint (!21 mm) (22) . Thus, in this study it was found that the RCA assay with CPD combination discs performed extremely well in the screening of, and differentiation between ESBL, AmpC and co-production of ESBL and AmpC in Enterobacteriaceae.
DISCUSSION
The present study proposes a rapid screening method using a RCA assay together with a CPD combined disc method to detect the presence of, and discriminate between, b-lactamases within 7 hr. The CA synergy test using the RCA assay with CPD combined discs to confirm the presence of ESBL production in Enterobacteriaceae detected all tested ESBL-producing isolates. Only one false-positive was found; this was in an OXA-48-producing isolate. Our findings agree with those reported by Derbyshire and colleagues (23) . They found that a CA synergy test using CPD was able to detect all 117 ESBL producers as indicated by a ! 5 mm greater zone diameter for CPD plus CA than for CPD alone. This synergy test was not able to detect ESBLs in the co-presence of AmpCs. Similarly, CPD performed extremely well in the screening of ESBL in K. pneumoniae and E. coli, but has poor sensitivity for K. oxytoca (24, 25) . The presence of ESBLs may also be masked by carbapenemases such as MBLs or KPCs (26) . Furthermore, not all OXA-48-variants exhibit significant carbapenemase activity; some OXA-48 variants, such as OXA-163 and OXA-405, are reportedly resistant to either carbapenem antibiotics or to extended-spectrum cephalosporins. These two variants are significantly inhibited by CA (27, 28) . We speculate that the OXA-48-producing isolate used in the present study may have weak carbapenemase activity, as indicated by the relatively large zone diameter for MER (22 mm) , and may also co-produce ESBL.
As to screening AmpC-producing isolates using the CX synergy test, the assay was able to detect all AmpC producers with two false positive results (100% sensitivity and 96.36% specificity). This result is consistent with many previous reports that CPD and CX synergy tests perform well in detecting these enzymes (18, 19, 29) . In one such study MAST D68C successfully detected almost all AmpC producers with only a few false-positive results (96.7% sensitivity and 96.9% specificity). The test was unable to detect weak production of AmpC b-lactamases by AmpC-producing isolates (19) . A similar result was reported by Ingram and colleagues, who found that MAST D68C exhibited sensitivity and specificity above 90% in detection of the presence of AmpC b-lactamase in Enterobacteriaceae (18) . In agreement with a previous study, a MAST-4 disc demonstrated good sensitivity (92%) and specificity (86.7%) in the detection of AmpC-producing nosocomial Klebsiella isolates (29) . The combined activity of ESBL and AmpC in the same strain can result in failure to detect the phenotype (30) . Co-production with AmpC b-lactamases can mask ESBL production such that CLSI confirmatory tests produce false-negative results (31) . Therefore, combining two or more specific b-lactamase inhibitors has the potential to exclude different types of b-lactamase in the same strain. In the present study, we used a CA plus CX synergy test to discriminate co-producers of ESBL and AmpC. This assay was able to detect eight co-producers of ESBL and AmpC; however, it detected only AmpC in one co-producer of ESBL and AmpC. This false-negative isolate was susceptible to CPD according to the CLSI breakpoint (22) . Our findings are similar to those of a previously mentioned study in which MAST D68C reportedly detected all eight ESBL and AmpC-co-producing isolates (18) .
When screening carbapenemase-producing isolates, a cut-off point of <25 mm is recommended for the MER disc because the zone diameter of MER in some OXA-48 like-producing bacteria is still in what is generally accepted as the susceptible range (!23 mm) (32, 33) . In the current study, we found that MER zone diameters against ESBL, AmpC, and Co-ESBL and AmpC ranged from 23-28 mm, whereas zone diameters ranged from 6.5-25 mm in carbapenemase-producing isolates. Only one OXA-48 producing isolate had a zone diameter of 25 mm. Thus, isolates showing zone diameters <25 mm for a 10 mg MER disc should be further investigated to detect the distinct type of carbapenemase (MBLs, KPCs and OXA-48 like carbapenemases) or AmpC plus porin loss. Carbapenem antibiotics are frequently used to treat infections caused by AmpC-and ESBL-producing gram-negative pathogens (34) . However, overuse of carbapenems can result in development of carbapenem resistance (13, 35) . Colistin, fosfomycin and tigecycline are among the antibiotics most frequently used to treat these cases (36) . Inclusion of a MER disc allows detection of meropenem resistance, which is important in guiding clinicians to appropriate antibiotic treatments.
To summarize, the combined disc test is commonly used in many microbiological laboratories, because it is very simple. The conventional method takes at least 18 hr to provide an inhibition zone diameter. The findings in the present study support the use of the RCA assay in that it shortens the time to obtaining results from disc diffusion susceptibility testing to within 7 hr. This assay also demonstrates excellent sensitivity and specificity for differentiation of ESBL, AmpC, and co-ESBL and AmpC-producing Enterobacteriaceae. The RCA assay could be combined with many commercially available discs, including MAST discs (Mast Group), and can also be used in CLSI ESBL confirmatory tests and any disc diffusion method. However, further validation and establishment of the robustness of this assay by testing a larger sample size of clinical isolates is still required. A rapid phenotypic method that can detect and differentiate the different types of b-lactamase would improve the ffectiveness of antibiotic administration and help to control dissemination of infections caused by these refractory bacteria.
